Denali Capital terminates business combination with Longevity Biomedical; SPAC seeks new target

Semnur Pharmaceuticals, Inc.

Merger agreement terminated effective June 26, 2024, by mutual agreement of Denali and Longevity Biomedical.
Original merger agreement was entered January 25, 2023; no reason for termination specified.
Denali and its sponsor will pursue alternative initial business combination; S-4 registration to be withdrawn.
Ancillary agreements also automatically terminate; certain customary survival provisions remain.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.